GlassScriptPhysician profile
Derrell Leggett
NPI 1306025630
$1,740.27
in general payments reported to CMS, 2019-2025
25 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $63.89 · 2021: $45.05 · 2022: $77.75 · 2023: $17.31 · 2024: $655 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Travel and Lodging: $284 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.79 |
| Travel and Lodging | $283.98 |
| Education | $243.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $731.53 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $226.90 | 2019-2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $119.12 | 2019-2024 | Xtampza |
| Pfizer INC. | $74.20 | 2019 | |
| Bausch Health US, LLC | $57.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.86 | 2019 | |
| Flowonix Medical Incorporated | $45.21 | 2019 | |
| Biodelivery Sciences International, INC. | $44.09 | 2019-2021 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Amgen INC. | $39.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $38.56 | 2019 | |
| Abbott Laboratories | $33.96 | 2020 | |
| Mdd US Operations, LLC | $27.62 | 2019 | |
| Sentynl Therapeutics, INC. | $25.54 | 2019 | |
| Daiichi Sankyo INC. | $24.83 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.46 | 2019 | |
| Globus Medical, INC. | $17.99 | 2025 | Senza |
| Horizon Therapeutics Plc | $16.76 | 2019 | |
| Redhill Biopharma INC. | $16.26 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $14.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2019 | |
| Shionogi INC | $13.12 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrell Leggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.